FDA clarifies policies for compounders as national GLP-1 supply …
WEBOct 2, 2024 · The U.S. Food and Drug Administration has determined the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has been resolved. Tirzepatide injection has been in...
Research shows GLP-1 drugs are effective but complex - UChicago …
WEBMay 30, 2024 · While experts caution against overusing GLP-1RAs or viewing them as a universal cure-all for obesity, physicians and researchers agree that the drugs are highly effective for weight management and Type 2 diabetes treatment.
Harvard Medical School Researcher Wins 2024 Lasker Award for …
WEBSep 19, 2024 · Harvard Medical School researcher Joel Habener has won the 2024 Lasker~DeBakey Clinical Medical Research Award for his discovery of glucagon-like peptide-1 (GLP-1), a molecule that has become the basis for therapies which have transformed the treatment of obesity.
Special Report: Potential Strategies for Addressing GLP-1 and Dual …
WEBApr 7, 2023 · Unexpected drug shortages of the long-acting glucagon-like peptide 1 (GLP-1) receptor agonists dulaglutide and semaglutide and the dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist tirzepatide emerged in late 2022 and have persisted through the first quarter of 2023 .
Pfizer Announces Topline Phase 2b Results of Oral GLP-1R …
WEBDec 1, 2023 · NEW YORK-- (BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced topline data from the Phase 2b clinical trial (NCT04707313) investigating its oral Glucagon-like peptide-1 receptor agonist (GLP-1RA) candidate, danuglipron (PF-06882961), in adults with obesity and without type 2 diabetes.
FDA approves first oral GLP-1 treatment for type 2 diabetes
WEBRybelsus is the first glucagon-like peptide (GLP-1) receptor protein treatment approved for use in the United States that does not need to be injected.
Glucagon-like peptide-1 receptor: mechanisms and advances in …
WEBSep 18, 2024 · The glucagon-like peptide-1 (GLP-1) receptor, known as GLP-1R, is a vital component of the G protein-coupled receptor (GPCR) family and is found primarily on the surfaces of various cell...
GLP1 agonists: current and future landscape of clinical trials for ...
WEBSep 6, 2024 · Agents that agonize glucagon-like peptide 1 receptors, including those that co-agonize other anorexigenic hormone receptors, lead to substantial weight loss and benefits in people with varying...
Pfizer Advances Development of Once-Daily Formulation of Oral GLP-1 ...
WEBJul 11, 2024 · NEW YORK-- (BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced that based on results from the ongoing pharmacokinetic study (NCT06153758), the company has selected its preferred once-daily modified release formulation for danuglipron, an oral glucagon-like peptide-1 (GLP-1) receptor agonist.
Summary of Glucagon-like Peptide-1 Receptor Agonists for Adults
WEBJun 29, 2023 · Glucagon-like peptide-1 (GLP-1) receptor agonists are approved by the Food and Drug Administration for treatment of type 2 diabetes mellitus and cardiovascular risk reduction in this cohort (see table). 1 In addition, GLP-1 …